MODKIFY
LIVE

Serial Number

79294183

Owner

CSL BEHRING GMBH

Attorney

Scott D. Woldow

Filing Date

Jul 24, 2020

Add to watchlist:

No watchlists yet
View on USPTO

MODKIFY Trademark

Serial Number: 79294183 • Registration: 6465740

MODKIFY is a trademark filed by CSL BEHRING GMBH on July 24, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

CSL BEHRING GMBH (101 trademarks)

EMIL-VON-BEHRING STRASSE 76
MARBURG (LAHN) , DE

Entity Type: 16

Trademark Details

Filing Date

July 24, 2020

Registration Date

August 31, 2021

Published for Opposition

June 15, 2021

Goods & Services

Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 4, 2022 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 7, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 10, 2022 FICS
FINAL DISPOSITION PROCESSED
Feb 10, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 30, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Aug 31, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 15, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jun 15, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 26, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 12, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 11, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 11, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 11, 2021 TROA
REFUSAL PROCESSED BY IB
Dec 20, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 3, 2020 RFCS
REFUSAL PROCESSED BY MPU
Dec 3, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 17, 2020 RFCR
NON-FINAL ACTION WRITTEN
Nov 16, 2020 CNRT
ASSIGNED TO EXAMINER
Nov 11, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 2, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 28, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 24, 2020 REPR